Literature DB >> 27994755

Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.

J Michael Ellis1, Michael D Altman1, Brandon Cash1, Andrew M Haidle1, Rachel L Kubiak1, Matthew L Maddess1, Youwei Yan1, Alan B Northrup1.   

Abstract

Optimization of a series of highly potent and kinome selective carbon-linked carboxamide spleen tyrosine kinase (Syk) inhibitors with favorable drug-like properties is described. A pervasive Ames liability in an analogous nitrogen-linked carboxamide series was obviated by replacement with a carbon-linked moiety. Initial efforts lacked on-target potency, likely due to strain induced between the hinge binding amide and solvent front heterocycle. Consideration of ground state and bound state energetics allowed rapid realization of improved solvent front substituents affording subnanomolar Syk potency and high kinome selectivity. These molecules were also devoid of mutagenicity risk as assessed via the Ames test using the TA97a Salmonella strain.

Entities:  

Keywords:  Spleen tyrosine kinase; intramolecular hydrogen bond; structure-based drug design

Year:  2016        PMID: 27994755      PMCID: PMC5150694          DOI: 10.1021/acsmedchemlett.6b00353

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.

Authors:  Greg Coffey; Francis DeGuzman; Mayuko Inagaki; Yvonne Pak; Suzanne M Delaney; Dan Ives; Andreas Betz; Zhaozhong J Jia; Anjali Pandey; Dale Baker; Stanley J Hollenbach; David R Phillips; Uma Sinha
Journal:  J Pharmacol Exp Ther       Date:  2011-10-31       Impact factor: 4.030

2.  Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Authors:  J Michael Ellis; Michael D Altman; Alan Bass; John W Butcher; Alan J Byford; Anthony Donofrio; Sheila Galloway; Andrew M Haidle; James Jewell; Nancy Kelly; Erica K Leccese; Sandra Lee; Matthew Maddess; J Richard Miller; Lily Y Moy; Ekundayo Osimboni; Ryan D Otte; M Vijay Reddy; Kerrie Spencer; Binyuan Sun; Stella H Vincent; Gwendolyn J Ward; Grace H C Woo; Chiming Yang; Hani Houshyar; Alan B Northrup
Journal:  J Med Chem       Date:  2015-02-16       Impact factor: 7.446

3.  Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.

Authors:  Matthew C Lucas; Niala Bhagirath; Eric Chiao; David M Goldstein; Johannes C Hermann; Pei-Yuan Hsu; Stephan Kirchner; Joshua J Kennedy-Smith; Andreas Kuglstatter; Christine Lukacs; John Menke; Linghao Niu; Fernando Padilla; Ying Peng; Liudmila Polonchuk; Aruna Railkar; Michelle Slade; Michael Soth; Daigen Xu; Preeti Yadava; Calvin Yee; Mingyan Zhou; Cheng Liao
Journal:  J Med Chem       Date:  2014-02-26       Impact factor: 7.446

Review 4.  Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.

Authors:  Marina Ulanova; Florentina Duta; Lakshmi Puttagunta; Alan D Schreiber; A Dean Befus
Journal:  Expert Opin Ther Targets       Date:  2005-10       Impact factor: 6.902

5.  Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.

Authors:  Lily Y Moy; Yanlin Jia; Michael Caniga; Gissela Lieber; Malgorzata Gil; Xiomara Fernandez; Erich Sirkowski; Richard Miller; Jessica P Alexander; Hyun-Hee Lee; John D Shin; J Michael Ellis; Hongmin Chen; Alan Wilhelm; Hongshi Yu; Stella Vincent; Richard W Chapman; Nancy Kelly; Emily Hickey; William M Abraham; Alan Northrup; Thomas Miller; Hani Houshyar; Michael A Crackower
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

6.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

7.  Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Mark C Genovese; David A Jones; Theresa K Musser; Elliott B Grossbard; Daniel B Magilavy
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

8.  Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.

Authors:  Armando G Villaseñor; Rama Kondru; Hoangdung Ho; Sandra Wang; Eva Papp; David Shaw; Jim W Barnett; Michelle F Browner; Andreas Kuglstatter
Journal:  Chem Biol Drug Des       Date:  2009-02-07       Impact factor: 2.817

Review 9.  Getting Syk: spleen tyrosine kinase as a therapeutic target.

Authors:  Robert L Geahlen
Journal:  Trends Pharmacol Sci       Date:  2014-06-26       Impact factor: 14.819

10.  Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Authors:  Cheng Liao; Jonathan Hsu; Yong Kim; Dong-Qing Hu; Daigen Xu; Jun Zhang; Achal Pashine; John Menke; Toni Whittard; Natasha Romero; Theresa Truitt; Michelle Slade; Christine Lukacs; Johannes Hermann; Mingyan Zhou; Matthew Lucas; Satwant Narula; Julie DeMartino; Seng-Lai Tan
Journal:  Arthritis Res Ther       Date:  2013-10-04       Impact factor: 5.156

View more
  2 in total

1.  Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

Authors:  Brandon A Vara; Samuel M Levi; Abdelghani Achab; David A Candito; Xavier Fradera; Charles A Lesburg; Shuhei Kawamura; Brian M Lacey; Jongwon Lim; Joey L Methot; Zangwei Xu; Haiyan Xu; Dustin M Smith; Jennifer A Piesvaux; J Richard Miller; Mark Bittinger; Sheila H Ranganath; David J Bennett; Erin F DiMauro; Alexander Pasternak
Journal:  ACS Med Chem Lett       Date:  2021-03-19       Impact factor: 4.345

Review 2.  Indolylboronic Acids: Preparation and Applications.

Authors:  Marek Čubiňák; Tereza Edlová; Peter Polák; Tomáš Tobrman
Journal:  Molecules       Date:  2019-09-28       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.